CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

ESMO Open. 2020 Nov;5(6):e001132. doi: 10.1136/esmoopen-2020-001132.

Authors

Elisa Agostinetto¹, Rafael Caparica², Evandro de Azambuja³

Affiliations

¹ Academic Trials Promoting Team, Institut Jules Bordet, Bruxelles, Belgium; Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy.
² Academic Trials Promoting Team, Institut Jules Bordet, Bruxelles, Belgium.
³ Academic Trials Promoting Team, Institut Jules Bordet, Bruxelles, Belgium. Electronic address: evandro.azambuja@bordet.be.

No abstract available

Keywords: CDK 4-6 inhibitors; HR-positive breast cancer; breast cancer.

Publication types

Editorial

MeSH terms

Breast Neoplasms* / drug therapy
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Female
Humans

Substances

CDK4 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6